Xenostegia tridentata
Xenostegia tridentata · Accepted scientific name
Scientific literature: Very Sparse (1 studies) · ★☆☆☆☆
Xenostegia tridentata is a botanical species that has garnered scientific interest due to its significant pharmacological potential. Research focusing on its ethanol extract and ethyl acetate subfraction has revealed a rich profile of bioactive compounds. Key phytochemicals identified in the plant include 3,5-Dicaffeoylquinic acid, Lutein, Luteolin 7-O-glucoside, and Quercetin 3-O-rhamnoside. These chemical constituents contribute to the plant's notable antidiabetic activities. Consequently, this species serves as a promising subject for further studies in natural medicine and metabolic health.
- Synonyms
- Ipomoea Tridentata · Convolvulus Tridentatus · 2 more
- Common names
- Not available
- Family
- Convolvulaceae
- Distribution
- Not available
- Plant Parts
- Not available
Classification
Common Names
Xenostegia tridentata is a versatile plant recognized by several distinct regional and descriptive names. It is widely known as the African morningvine, a title that reflects its botanical lineage. In certain circles, it is also referred to as the Miniature Morning Glory or the Narrow-leaved Merremia. Local naming traditions further expand its identity, with names such as Geeltrompettertjie and Mudiarkunthal being used to identify it. These diverse monikers highlight the plant's widespread recognition across various cultural and linguistic landscapes.
Sources: Catalogue of Life (COL)
Synonyms
Xenostegia tridentata is a botanical species that has been categorized under several different names throughout its classification history. Because of shifting taxonomic understandings, it is frequently identified by the synonym Convolvulus tridentatus. Researchers also recognize the plant through its association with Evolvulus tridentatus in various scientific records. Furthermore, the species has been historically referred to as Ipomoea tridentata in older literature. Finally, the name Merremia tridentata serves as another valid synonym used to describe this specific plant.
Sources: The World Checklist of Vascular Plants (WCVP)
Taxonomy
Xenostegia tridentata is a distinct botanical species belonging to the kingdom Plantae. Within this vast kingdom, the plant is classified under the class Equisetopsida. It further occupies a specific niche as a member of the order Solanales. Taxonomically, it is nested within the family Convolvulaceae, showcasing its evolutionary connections. Ultimately, this plant is defined by its placement in the unique genus Xenostegia.
| Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Phylum | Streptophyta |
| Class | Equisetopsida |
| Subclass | Magnoliidae |
| Order | Solanales |
| Family | Convolvulaceae |
| Genus | Xenostegia |
Sources: The World Checklist of Vascular Plants (WCVP)
Distribution
Geographic Regions
Xenostegia tridentata is a distinctive plant species with a wide distribution across the African continent. Its presence is particularly noted throughout East Tropical Africa, where it can be found in Kenya, Tanzania, and Uganda. Beyond the eastern regions, the species also extends into Northeast Tropical Africa. In these northern stretches, it inhabits the landscapes of both Chad and Ethiopia. This broad range highlights the plant's adaptability to various diverse ecological zones within Africa.
Sources: The World Checklist of Vascular Plants (WCVP)
Identification
Morphology
Xenostegia tridentata is a distinctive herb characterized by its obligatory climbing habit. This specialized growth form allows the plant to scale surrounding vegetation to reach optimal sunlight. While its height can technically begin from a minimum of 0 m, it typically establishes a significant presence in its ecosystem. The plant generally achieves a minimum height of 2.5 m as it matures. Ultimately, this climbing species can reach a maximum height of approximately 5 m.
Sources: Global Inventory of Floras and Traits (GIFT)
Biological Activities
Xenostegia tridentata, also known by its synonym Merremia tridentata, demonstrates significant potential as a natural agent for managing diabetes. Research indicates that both the stem-ethanol extract and its flavonoid-rich fraction possess potent antidiabetic and hypoglycemic properties. In vivo studies using alloxan-induced diabetic mice revealed that these extracts can outperform standard reference drugs like metformin and glibenclamide. The effectiveness of the plant is largely attributed to specific flavonoids such as cynaroside, cosmosiin, and quercitrin, which inhibit key enzymes like α-amylase and α-glucosidase. Ultimately, these combined in vitro, in silico, and in vivo findings suggest that the plant is a promising candidate for future pharmaceutical development.
Compounds
Xenostegia tridentata is a plant rich in bioactive compounds that demonstrate significant therapeutic potential. Scientific investigations have confirmed that this species contains lutein, which exhibits potent anticancer activities by inhibiting hyaluronidase in lung cancer cells. Furthermore, metabolomic analyses have identified several key flavonoids within its ethyl acetate subfraction, including luteolin 7-O-glucoside. The plant also contains quercetin 3-O-rhamnoside and kaempferol 3-O-rhamnoside, both of which play vital roles in its anti-allergic properties. Together, these constituents highlight the complex chemical profile of the plant and its ability to modulate various biological processes.
Conditions
Xenostegia tridentata, also referred to as Merremia tridentata, demonstrates significant potential in managing physiological responses through its various chemical constituents. Research indicates that the plant exhibits promising anti-allergic activity, performing comparably to known agents like dexamethasone in inhibiting mast cell degranulation. Studies on its safety profile show that the plant extract can be evaluated for acute toxicity, revealing no treatment-related mortality even at high single doses. Furthermore, its sub-acute toxicity was assessed, establishing a no-observed-adverse-effect level at 15,000 mg/kg/day to ensure pharmaceutical safety. These findings collectively highlight the plant's utility in addressing both allergic reactions and toxicological thresholds.
Preparations
Xenostegia tridentata is prepared as an ethanol extract to investigate its potential in vivo and in vitro anti-allergic activities. This crude ethanol extract demonstrated promising results when compared to established anti-allergic agents like dexamethasone and ketotifen fumarate. Furthermore, the plant is processed into an ethyl acetate subfraction to isolate more potent bioactive components. This specific ethyl acetate subfraction exhibited the highest anti-allergic activity among various sub-partitions tested. The superior performance of this subfraction is attributed to its high abundance of total phenolic and flavonoid contents.